| |
| |
|
| Insider
Information: |
Foehr Matthew W |
| Relationship: |
President and CEO, Dir... |
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
3,948,737 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$33,186,682 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
3,948,737 |
|
|
| Total
Value |
$33,186,682 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
13
|
4
|
|
Stock
price went up :
|
6
|
0
|
| Stock
price went down : |
7
|
4
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-4.0
|
| Percentage
Gain/Loss : |
 32.7%
|
 -89.3%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ligand Pharmaceuticals Inc |
LGND |
Former Executive Officer |
2022-11-01 |
162,187 |
2011-04-18 |
0 |
Premium* |
|
|
Viking Therapeutics, Inc. |
VKTX |
Director |
2022-05-02 |
111,250 |
2015-05-04 |
0 |
Premium* |
|
|
Qualigen Therapeutics Inc |
QLGN |
Director |
2020-04-10 |
138,635 |
2015-06-24 |
0 |
Premium* |
|
|
OmniAb, Inc |
OABI |
President and CEO, Dir... |
2024-05-24 |
3,536,665 |
2022-11-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
136 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| OABI |
OmniAb, Inc |
President & CEO |
• • – |
2023-02-15 |
4 |
D |
$3.80 |
$64,927 |
D/D |
(17,086) |
1,889,039 |
0 |
- |
|
| OABI |
OmniAb, Inc |
President and CEO |
• • – |
2022-11-01 |
4/A |
A |
$0.00 |
$0 |
D/D |
1,431,618 |
3,296,665 |
0 |
- |
|
| OABI |
OmniAb, Inc |
President and CEO |
• • – |
2023-08-14 |
4 |
B |
$5.48 |
$246,600 |
D/D |
45,000 |
2,332,919 |
2.81 |
% |
|
| OABI |
OmniAb, Inc |
President and CEO |
• • – |
2023-11-10 |
4 |
B |
$4.27 |
$405,517 |
D/D |
95,000 |
2,427,919 |
0.01 |
% |
|
| OABI |
OmniAb, Inc |
President and CEO |
• • – |
2024-03-22 |
4 |
B |
$5.19 |
$1,167,750 |
D/D |
225,000 |
2,908,803 |
2.81 |
% |
|
| OABI |
OmniAb, Inc |
President and CEO |
• • – |
2024-03-27 |
4 |
OE |
$3.68 |
$907,023 |
D/D |
243,613 |
3,152,416 |
0 |
- |
|
| OABI |
OmniAb, Inc |
President and CEO |
• • – |
2024-04-07 |
4 |
D |
$5.31 |
$98,113 |
D/D |
(18,477) |
3,170,397 |
0 |
- |
|
| OABI |
OmniAb, Inc |
President and CEO |
• • – |
2024-04-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
36,458 |
3,188,874 |
0 |
- |
|
| OABI |
OmniAb, Inc |
President and CEO |
• • – |
2024-05-24 |
4 |
B |
$4.42 |
$1,059,840 |
D/D |
240,000 |
3,536,665 |
2.81 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2015-06-22 |
4 |
AS |
$95.77 |
$2,222,815 |
D/D |
(23,046) |
68,128 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2015-06-22 |
4 |
OE |
$9.97 |
$249,709 |
D/D |
25,046 |
70,128 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2015-06-26 |
4 |
OE |
$9.97 |
$124,625 |
D/D |
12,500 |
82,628 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2015-06-26 |
4 |
AS |
$100.97 |
$1,262,125 |
D/D |
(12,500) |
70,128 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2015-06-29 |
4 |
OE |
$9.97 |
$24,925 |
D/D |
2,500 |
72,628 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2016-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
5,676 |
78,304 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2016-02-15 |
4 |
D |
$85.97 |
$141,163 |
D/D |
(1,642) |
76,662 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2016-03-17 |
4 |
OE |
$9.97 |
$86,241 |
D/D |
8,650 |
78,912 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2016-03-17 |
4 |
S |
$96.70 |
$618,880 |
D/D |
(6,400) |
76,662 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2016-08-05 |
4 |
S |
$122.14 |
$1,526,750 |
D/D |
(12,500) |
78,912 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2016-08-05 |
4 |
OE |
$9.97 |
$124,625 |
D/D |
12,500 |
91,412 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2016-08-08 |
4 |
OE |
$9.97 |
$41,126 |
D/D |
4,125 |
83,037 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2017-02-15 |
4 |
D |
$104.28 |
$246,831 |
D/D |
(2,367) |
80,670 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2017-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
12,783 |
90,720 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2017-02-24 |
4 |
D |
$100.38 |
$274,339 |
D/D |
(2,733) |
83,176 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President and COO |
• – – |
2017-03-02 |
4 |
OE |
$9.97 |
$68,584 |
D/D |
6,879 |
97,599 |
0 |
- |
|
136 Records found
|
|
Page 3 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
